Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shuji Murakami

Showing results (11-20 of 119) with videos related to

Pageof 12
Sort By:
Frontiers in Oncology|April 28, 2023
Case report: anaplastic lymphoma kinase (<i>ALK</i>) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumabNaoko Shigeta, Shuji Murakami, Tomoyuki Yokose, et al.
Journal of Experimental Therapeutics & Oncology|January 15, 2014
Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancerFumihiro Oshita, Shuji Murakami, Tetsuro Kondo, et al.
Journal of Experimental Therapeutics & Oncology|December 28, 2019
Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-typeShuji Murakami, Haruhiro Saito, Tetsuro Kondo, et al.
Neuroscience Research|July 19, 2005
Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustlyShuji Murakami, Hiroki Imbe, Yoshihiro Morikawa, et al.
Pain|November 25, 2004
The effects of acute and chronic restraint stress on activation of ERK in the rostral ventromedial medulla and locus coeruleusHiroki Imbe, Shuji Murakami, Keiichiro Okamoto, et al.
Lung Cancer (Amsterdam, Netherlands)|April 21, 2009
Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cellsHideyo Kuroda, Mitsuhiro Takeno, Shuji Murakami, et al.
Onkologie|February 8, 2012
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 monthsHaruhiro Saito, Shuji Murakami, Tetsuro Kondo, et al.
Cancer Chemotherapy and Pharmacology|January 19, 2013
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutationShuji Murakami, Fumihiro Oshita, Makiko Sugiura, et al.
Internal Medicine (Tokyo, Japan)|January 4, 2021
Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab TherapyShuji Murakami, Ryou Usui, Yoshiro Nakahara, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2012
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancerFumihiro Oshita, Makiko Sugiura, Shuji Murakami, et al.
Pageof 12

Showing results (11-20 of 119) with videos related to

Sort By:
Pageof 12
Frontiers in Oncology|April 28, 2023
Case report: anaplastic lymphoma kinase (<i>ALK</i>) rearranged adenocarcinoma with high level of microsatellite instability response to pembrolizumabNaoko Shigeta, Shuji Murakami, Tomoyuki Yokose, et al.
Journal of Experimental Therapeutics & Oncology|January 15, 2014
Prospective study of paclitaxel and irinotecan for elderly patients with unresectable non-small cell lung cancerFumihiro Oshita, Shuji Murakami, Tetsuro Kondo, et al.
Journal of Experimental Therapeutics & Oncology|December 28, 2019
Phase II study of bevacizumab, cisplatin, and pemetrexed in advanced non-squamous non-small cell lung cancer (NS-NSCLC) with EGFR wild-typeShuji Murakami, Haruhiro Saito, Tetsuro Kondo, et al.
Neuroscience Research|July 19, 2005
Chronic stress, as well as acute stress, reduces BDNF mRNA expression in the rat hippocampus but less robustlyShuji Murakami, Hiroki Imbe, Yoshihiro Morikawa, et al.
Pain|November 25, 2004
The effects of acute and chronic restraint stress on activation of ERK in the rostral ventromedial medulla and locus coeruleusHiroki Imbe, Shuji Murakami, Keiichiro Okamoto, et al.
Lung Cancer (Amsterdam, Netherlands)|April 21, 2009
Inhibition of heme oxygenase-1 with an epidermal growth factor receptor inhibitor and cisplatin decreases proliferation of lung cancer A549 cellsHideyo Kuroda, Mitsuhiro Takeno, Shuji Murakami, et al.
Onkologie|February 8, 2012
Effectiveness of erlotinib in advanced non-small cell lung cancer in cases of gefitinib resistance after treatment of more than 6 monthsHaruhiro Saito, Shuji Murakami, Tetsuro Kondo, et al.
Cancer Chemotherapy and Pharmacology|January 19, 2013
Phase I/II study of amrubicin in combination with S-1 as second-line chemotherapy for non-small-cell lung cancer without EGFR mutationShuji Murakami, Fumihiro Oshita, Makiko Sugiura, et al.
Internal Medicine (Tokyo, Japan)|January 4, 2021
Readministration of Pembrolizumab after Treatment of Tuberculosis Activated by Initial Pembrolizumab TherapyShuji Murakami, Ryou Usui, Yoshiro Nakahara, et al.
Cancer Chemotherapy and Pharmacology|November 6, 2012
Phase II study of nedaplatin and irinotecan in patients with extensive small-cell lung cancerFumihiro Oshita, Makiko Sugiura, Shuji Murakami, et al.
Pageof 12